Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.

Chakravarty D, Pedraza AM, Cotari J, Liu AH, Punko D, Kokroo A, Huse JT, Altan-Bonnet G, Brennan CW.

Sci Rep. 2017 Aug 22;7(1):9043. doi: 10.1038/s41598-017-08940-9.

2.

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).

Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, Birnbaum D, Dirix LY, Ueno N, Carter M, Rains J, Ramachandran A, Bertucci F, van Golen KL.

Neoplasia. 2017 Jul;19(7):564-573. doi: 10.1016/j.neo.2017.03.002. Epub 2017 Jun 10.

3.

Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Wang L, Busam KJ, Benayed R, Cimera R, Wang J, Denley R, Rao M, Aryeequaye R, Mullaney K, Cao L, Ladanyi M, Hameed M.

J Mol Diagn. 2017 May;19(3):387-396. doi: 10.1016/j.jmoldx.2016.11.005.

PMID:
28433076
4.

Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Lucca LE, Hafler DA.

Immunol Rev. 2017 Mar;276(1):9-25. doi: 10.1111/imr.12529. Review.

PMID:
28258696
5.

The Role of PDGFs and PDGFRs in Colorectal Cancer.

Manzat Saplacan RM, Balacescu L, Gherman C, Chira RI, Craiu A, Mircea PA, Lisencu C, Balacescu O.

Mediators Inflamm. 2017;2017:4708076. doi: 10.1155/2017/4708076. Epub 2017 Jan 10. Review.

6.

Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.

Kambach DM, Halim AS, Cauer AG, Sun Q, Tristan CA, Celiku O, Kesarwala AH, Shankavaram U, Batchelor E, Stommel JM.

Oncotarget. 2017 Feb 28;8(9):14860-14875. doi: 10.18632/oncotarget.14740.

7.

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

Lindberg OR, McKinney A, Engler JR, Koshkakaryan G, Gong H, Robinson AE, Ewald AJ, Huillard E, David James C, Molinaro AM, Shieh JT, Phillips JJ.

Oncotarget. 2016 Nov 29;7(48):79101-79116. doi: 10.18632/oncotarget.12600.

8.

Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.

Ki DH, He S, Rodig S, Look AT.

Oncogene. 2017 Feb 23;36(8):1058-1068. doi: 10.1038/onc.2016.269. Epub 2016 Aug 1.

9.

A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.

Cimino PJ, Bredemeyer A, Abel HJ, Duncavage EJ.

Exp Mol Pathol. 2015 Jun;98(3):568-73. doi: 10.1016/j.yexmp.2015.04.006. Epub 2015 Apr 22.

10.

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.

Navis AC, van Lith SA, van Duijnhoven SM, de Pooter M, Yetkin-Arik B, Wesseling P, Hendriks WJ, Venselaar H, Timmer M, van Cleef P, van Bergen En Henegouwen P, Best MG, Wurdinger TD, Tops BB, Leenders WP.

Acta Neuropathol. 2015 Jul;130(1):131-44. doi: 10.1007/s00401-015-1420-5. Epub 2015 Apr 11.

11.

Double minute amplification of mutant PDGF receptor α in a mouse glioma model.

Zou H, Feng R, Huang Y, Tripodi J, Najfeld V, Tsankova NM, Jahanshahi M, Olson LE, Soriano P, Friedel RH.

Sci Rep. 2015 Feb 16;5:8468. doi: 10.1038/srep08468.

12.

Platelet-derived growth factor in glioblastoma-driver or biomarker?

Westermark B.

Ups J Med Sci. 2014 Nov;119(4):298-305. doi: 10.3109/03009734.2014.970304. Epub 2014 Oct 24. Review.

13.

Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.

Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, Geng N.

Onco Targets Ther. 2014 Sep 26;7:1761-8. doi: 10.2147/OTT.S68773. eCollection 2014.

14.

Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC.

Cancer Cell. 2014 Aug 11;26(2):288-300. doi: 10.1016/j.ccr.2014.06.005.

15.

The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis.

Zhai PF, Wang F, Su R, Lin HS, Jiang CL, Yang GH, Yu J, Zhang JW.

J Biol Chem. 2014 Aug 15;289(33):22600-13. doi: 10.1074/jbc.M114.547380. Epub 2014 Jun 30.

16.

Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.

Haynes HR, Camelo-Piragua S, Kurian KM.

Front Oncol. 2014 Mar 24;4:47. doi: 10.3389/fonc.2014.00047. eCollection 2014. Review.

17.

Role of receptor tyrosine kinases and their ligands in glioblastoma.

Carrasco-García E, Saceda M, Martínez-Lacaci I.

Cells. 2014 Apr 4;3(2):199-235. doi: 10.3390/cells3020199.

18.

The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma.

Carvalho D, Mackay A, Bjerke L, Grundy RG, Lopes C, Reis RM, Jones C.

Acta Neuropathol Commun. 2014 Feb 18;2:23. doi: 10.1186/2051-5960-2-23.

19.

Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA.

Chen D, Zuo D, Luan C, Liu M, Na M, Ran L, Sun Y, Persson A, Englund E, Salford LG, Renström E, Fan X, Zhang E.

PLoS One. 2014 Jan 29;9(1):e87281. doi: 10.1371/journal.pone.0087281. eCollection 2014.

20.

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM.

Nat Rev Cancer. 2014 Feb;14(2):92-107. doi: 10.1038/nrc3655. Review.

Supplemental Content

Support Center